Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 27 Sales growth driven by the diabetes and obesity franchise Novo Nordisk reported quarterly sales by therapy Reported sales split by product segments for first nine months of 2018 Premix insulin GLP-1 Haemophilia Fast-acting insulin Other diabetes and obesity Other biopharmaceuticals Diabetes and obesity Haemophilia² Long-acting insulin bDKK NorditropinⓇ Other Human insulin 35 Growth disorders Reported sales 30 CAGR¹: 8.2% 25 -2.9% 20 4.8% 15 2.6% 9.8% 10 5 0 Q3 2008 Q3 2018 1 CAGR for 10-year period 2 Haemophilia comprises NovoSeven®, NovoThirteenⓇ, NovoEight® and Refixia® changing diabetes® 1% 6% 19% 9% 7% 9% 23% 17% 9% Sales of DKK 82.1 billion (2%) novo nordisk

View entire presentation